Results 81 to 90 of about 14,491 (226)

Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology [PDF]

, 2017
Background: ALK-rearranged lung cancers exhibit specific pathologic and clinical features and are responsive to anti-ALK therapies. Therefore, the detection of ALK-rearrangement is fundamental for personalized lung cancer therapy. Recently, new molecular
A Cesano, Adriana Cruvinel Carloni, Adriane F. Evangelista, AP Becker, AS Crystal, AT Shaw, Cristovam Scapulatempo-Neto, DR Camidge, DW-S Wong, EL Kwak, EM Gaughan, FH Wilson, Flávia E. de Paula, I Dagogo-Jack, Iberê Cauduro Soares, J Wu, JM Heuckmann, Jose Elias Miziara, JS Reis-Filho, K McKeage, K Rikova, K Takeuchi, LS Yamane, M Soda, Maicon F. Zanon, Maressa Ferreira-Neto, Mariana Andozia Morini, ME Lira, MM Kulkarni, MW Wynes, Pedro de Marchi, R Roskoski, Rui M. Reis, S-H Jung, SM Ali, SW Morris, T-M Rogers, YP Mossé   +37 more
core   +2 more sources

ALK‐Positive Histiocytosis With Unilateral Breast Involvement: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT APH is a rare disorder characterized by the proliferation of ALK‐expressing histiocytes with variable anatomical involvement; however, mammary involvement is exceptionally rare. A 32‐year‐old woman presented with a painless right breast mass. Ultrasound identified a 9 × 8 mm hypoechoic nodule, categorized as BI‐RADS 4A.
Xuechun Liu, Dong Ren, Yanfang Liang
wiley   +1 more source

Cycling Through Uncertainty: The Psychological Experiences of Individuals With Lung Cancer Receiving Immunotherapy And/Or Targeted Therapy

Psycho-Oncology, Volume 35, Issue 1, January 2026.
ABSTRACT Background The recent developments in immunotherapy and targeted therapy drugs offer a new hope for prolonging overall survival and improving quality of life in individuals with advanced lung cancer. However, treatment response to these drugs is variable and unpredictable and early research indicates that these individuals are living with ...
Alanna K. Chu, Emma Kearns, Celeste Holy, Paul Wheatley‐Price, Rinat Nissim, Tim Aubry, Sophie Lebel   +6 more
wiley   +1 more source

ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.

PLoS ONE, 2020
BackgroundWe sought to assess the relative effects of individual anaplastic lymphoma kinase (ALK) inhibitors for the treatment of non-small cell lung cancer (NSCLC).MethodsWe searched MEDLINE, Embase, Cochrane CENTRAL, and grey literature (July 23, 2019)
Jesse Elliott, Zemin Bai, Shu-Ching Hsieh, Shannon E Kelly, Li Chen, Becky Skidmore, Said Yousef, Carine Zheng, David J Stewart, George A Wells   +9 more
doaj   +1 more source

Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. [PDF]

, 2019
Advanced non-small cell lung cancer (NSCLC) is a complex disease comprising molecularly distinct tumor types, each with a unique biology that is becoming increasingly better characterized.
Abdel Karim, Nagla, Kelly, Karen
core  

Comparative efficacy of targeted therapies in patients with non-small cell lung cancer: a network meta-analysis of clinical trials [PDF]

, 2020
This study aims to investigate the efficacy of targeted therapies in the treatment of non-small cell lung cancer (NSCLC) by using a network meta-analysis of clinical trials.
Hoang, T., Ju, W., Kim, J., Myung, S.K., Pham, T.T.   +4 more
core   +1 more source

Comparative Analysis of a Dual DNA–RNA Panel and a DNA‐Only Panel for Sarcoma: Real‐World Data From a Nationwide Genomic Database

Cancer Science, Volume 117, Issue 1, Page 156-168, January 2026.
Dual DNA–RNA panel with matched tumor–normal testing may improve diagnostic accuracy and inform treatment decisions in the routine clinical management of sarcoma. ABSTRACT Next‐generation sequencing‐based comprehensive cancer genomic profiling is promising in cancer management; however, most studies rely on tumor‐only DNA panels from single ...
Eiji Nakata, Kiichiro Ninomiya, Tatsunori Osone, Daisuke Ennishi, Shuta Tomida, Tomohiro Fujiwara, Toshiyuki Kunisada, Mashu Futagawa, Akira Hirasawa, Shinichi Toyooka, Toshifumi Ozaki   +10 more
wiley   +1 more source

Comparison of the effectiveness of alectinib versus crizotinib followed by alectinib in patients with ALK-positive advanced non-small-cell lung cancer in real-world setting and in the ALEX study

Translational Lung Cancer Research
Background Alectinib has been established as a standard of care for patients with treatment-naive anaplastic lymphoma kinase-rearranged (ALK-positive) advanced non-small-cell lung cancer (NSCLC); however, it has rarely been compared with the sequential ...
Xue Yang, Yutao Liu, Gen Lin, Jinliang Wang, Yudong Wang, Yan Zhang, Qinxiang Guo, Fei Liang, Jun Zhao, Bo Jin, Xiaorong Dong   +10 more
semanticscholar   +1 more source

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib [PDF]

, 2017
Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments.
Caglevic, C., Corrales, L., Giallombardo, M., Listi', A., Nogueira, A., Passiglia, F., Raez, L., Rolfo, C., Santos, E.   +8 more
core   +2 more sources

SMARCA4‐Deficient Undifferentiated Thoracic Tumor: Clinical Features and Prognosis of a Case Series and Literature Review

The Clinical Respiratory Journal, Volume 20, Issue 1, January 2026.
Our manuscript presents detailed presentations of case series of thoracic SMARCA4‐UT, and we report a unique case of diaphragmatic metastases and, interestingly, the occurrence of brain metastasis in one patient, which is a rare phenomenon in SMARCA4‐UT.
Fangzhen Shan, Shuntao Liang, Youwen Zhang, Wei Wu, Guangxia Yang, Mei Yan, Xuemei Zhang, Yumao Miao, Linlin Liu, Jingjing Cai, Zhitao Shi, Bangdong Liu, Nannan Zhang   +12 more
wiley   +1 more source